loading
Schlusskurs vom Vortag:
$7.31
Offen:
$7.43
24-Stunden-Volumen:
72,170
Relative Volume:
0.54
Marktkapitalisierung:
$188.46M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.38M
KGV:
-5.3333
EPS:
-1.41
Netto-Cashflow:
$-15.54M
1W Leistung:
-2.84%
1M Leistung:
-16.26%
6M Leistung:
+39.52%
1J Leistung:
+15.51%
1-Tages-Spanne:
Value
$7.32
$7.59
1-Wochen-Bereich:
Value
$7.25
$8.055
52-Wochen-Spanne:
Value
$4.44
$11.80

Nuvectis Pharma Inc Stock (NVCT) Company Profile

Name
Firmenname
Nuvectis Pharma Inc
Name
Telefon
360-837-7232
Name
Adresse
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Name
Mitarbeiter
13
Name
Twitter
Name
Nächster Verdiensttermin
2024-08-07
Name
Neueste SEC-Einreichungen
Name
NVCT's Discussions on Twitter

Vergleichen Sie NVCT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NVCT
Nuvectis Pharma Inc
7.52 188.46M 0 -22.38M -15.54M -1.41
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-02 Eingeleitet Maxim Group Buy
2025-03-17 Eingeleitet Laidlaw Buy
2022-07-13 Eingeleitet Ladenburg Thalmann Buy

Nuvectis Pharma Inc Aktie (NVCT) Neueste Nachrichten

pulisher
Jun 18, 2025

Nuvectis Pharma: Still Interesting, But Still Too Risky To Jump In - Seeking Alpha

Jun 18, 2025
pulisher
Jun 18, 2025

Insiders of Nuvectis Pharma, Inc. (NASDAQ:NVCT) must be disappointed as stock fell 10% after recent purchases - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Insider Stock Buying Of Nuvectis Pharma Delivers Return On US$2.19m Investment - simplywall.st

Jun 18, 2025
pulisher
Jun 13, 2025

Nuvectis Pharma Approves Proposals at Annual Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

Nuvectis Pharma, Inc. (NASDAQ:NVCT) Shares Sold by Two Sigma Investments LP - Defense World

Jun 13, 2025
pulisher
Jun 13, 2025

Millennium Management LLC Reduces Holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World

Jun 13, 2025
pulisher
Jun 10, 2025

(NVCT) Investment Analysis - news.stocktradersdaily.com

Jun 10, 2025
pulisher
Jun 10, 2025

Squarepoint Ops LLC Invests $103,000 in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect? - MSN

Jun 09, 2025
pulisher
Jun 04, 2025

Nuvectis Pharma, Inc. (NASDAQ:NVCT) Shares Bought by Northern Trust Corp - Defense World

Jun 04, 2025
pulisher
May 29, 2025

(NVCT) On The My Stocks Page - news.stocktradersdaily.com

May 29, 2025
pulisher
May 20, 2025

Cubist Systematic Strategies LLC Invests $34,000 in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World

May 20, 2025
pulisher
May 18, 2025

When (NVCT) Moves Investors should Listen - news.stocktradersdaily.com

May 18, 2025
pulisher
May 16, 2025

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference - GlobeNewswire

May 16, 2025
pulisher
May 12, 2025

Nuvectis pharma investor Charles Mosseri Marlio buys $247k in stock By Investing.com - Investing.com India

May 12, 2025
pulisher
May 10, 2025

Q2 EPS Estimates for Nuvectis Pharma Lifted by HC Wainwright - Defense World

May 10, 2025
pulisher
May 10, 2025

Roth Capital Forecasts Stronger Earnings for Nuvectis Pharma - Defense World

May 10, 2025
pulisher
May 09, 2025

Nuvectis Pharma Launches New $60M Stock Offering Program - TipRanks

May 09, 2025
pulisher
May 09, 2025

Nuvectis Pharma launches public stock offering - MSN

May 09, 2025
pulisher
May 08, 2025

(NVCT) Investment Report - news.stocktradersdaily.com

May 08, 2025
pulisher
May 08, 2025

Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

May 08, 2025
pulisher
May 07, 2025

Nuvectis Pharma Reports Q1 2025 Progress and Financials - TipRanks

May 07, 2025
pulisher
May 06, 2025

Nuvectis Pharma reports Q1 EPS (27c) vs (25c) last year - TipRanks

May 06, 2025
pulisher
May 06, 2025

Nuvectis (NVCT) Advances Clinical Programs with Promising Updates | NVCT Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewswire

May 06, 2025
pulisher
May 03, 2025

Nuvectis Pharma’s (NVCT) “Buy” Rating Reiterated at HC Wainwright - Defense World

May 03, 2025
pulisher
May 01, 2025

Buy Rating for Nuvectis Pharma: Promising Phase 1 Trial Results of NXP900 Highlight Potential in Combination Therapies - TipRanks

May 01, 2025
pulisher
Apr 30, 2025

Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025 - Insider Monkey

Apr 30, 2025
pulisher
Apr 29, 2025

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting - The Manila Times

Apr 29, 2025
pulisher
Apr 29, 2025

Nuvectis Pharma, Inc. Announces Positive Phase 1a Data for NXP900 Demonstrating Robust Pharmacodynamic Responses and Acceptable Safety Profile - Nasdaq

Apr 29, 2025
pulisher
Apr 29, 2025

Breakthrough: Nuvectis NXP900 Cancer Drug Achieves 90% Target Inhibition in Phase 1 Trial - Stock Titan

Apr 29, 2025
pulisher
Apr 25, 2025

Nuvectis Pharma (NASDAQ:NVCT) Trading 5.3% Higher – Here’s What Happened - Defense World

Apr 25, 2025
pulisher
Apr 23, 2025

(NVCT) Trading Signals - news.stocktradersdaily.com

Apr 23, 2025
pulisher
Apr 18, 2025

Is Nuvectis Pharma Inc (NASDAQ: NVCT) A Good Pick For New Investors Now? - Stocksregister

Apr 18, 2025
pulisher
Apr 16, 2025

Nuvectis Pharma prices 2.7M shares at $5.00 in underwritten public offering - MSN

Apr 16, 2025
pulisher
Apr 15, 2025

Nuvectis pharma investor acquires $1.2 million in stock - MSN

Apr 15, 2025
pulisher
Apr 15, 2025

Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$36m last week; individual investors who hold 48% profited and so did insiders - simplywall.st

Apr 15, 2025
pulisher
Apr 14, 2025

SCHD ETF News, 4/14/2025 - The Globe and Mail

Apr 14, 2025
pulisher
Apr 08, 2025

Top 5 Small-cap Pharma Stocks in 2025 - Investing News Network

Apr 08, 2025
pulisher
Apr 06, 2025

When the Price of (NVCT) Talks, People Listen - news.stocktradersdaily.com

Apr 06, 2025
pulisher
Apr 05, 2025

Nuvectis Pharma (NASDAQ:NVCT) and Edesa Biotech (NASDAQ:EDSA) Critical Analysis - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

Maxim Group Begins Coverage on Nuvectis Pharma (NASDAQ:NVCT) - Defense World

Apr 04, 2025
pulisher
Apr 02, 2025

Maxim Group Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - Nasdaq

Apr 02, 2025
pulisher
Apr 02, 2025

Maxim Initiates Nuvectis Pharma at Buy With $17 Price Target - MarketScreener

Apr 02, 2025
pulisher
Mar 29, 2025

Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference - MarketScreener

Mar 29, 2025
pulisher
Mar 27, 2025

CEO ClipsOrvana Minerals: Expanding Gold, Silver & Copper Production Across Key Global Regions - The Globe and Mail

Mar 27, 2025
pulisher
Mar 26, 2025

Nuvectis Pharma Announces Upcoming Presentations for NXP900 - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

New Cancer Treatment Breakthrough: NXP900 Data Showcase at Major AACR Conference - Stock Titan

Mar 26, 2025
pulisher
Mar 21, 2025

Nuvectis Pharma, Inc. (NASDAQ:NVCT) Sees Large Decline in Short Interest - Defense World

Mar 21, 2025
pulisher
Mar 18, 2025

Nuvectis Pharma (NASDAQ:NVCT) Now Covered by Analysts at Laidlaw - Defense World

Mar 18, 2025
pulisher
Mar 17, 2025

Laidlaw & Co. Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - Nasdaq

Mar 17, 2025

Finanzdaten der Nuvectis Pharma Inc-Aktie (NVCT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Nuvectis Pharma Inc-Aktie (NVCT) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Mosseri Marlio Charles
10% Owner
Jun 18 '25
Buy
8.05
28,043
225,746
2,976,203
Mosseri Marlio Charles
10% Owner
Jun 17 '25
Buy
8.11
5,399
43,786
2,948,160
Mosseri Marlio Charles
10% Owner
May 12 '25
Buy
8.11
21,167
171,664
2,942,761
Mosseri Marlio Charles
10% Owner
May 06 '25
Buy
8.59
12,444
106,955
2,896,565
Mosseri Marlio Charles
10% Owner
May 07 '25
Buy
8.59
12,317
105,770
2,908,882
Mosseri Marlio Charles
10% Owner
May 08 '25
Buy
8.65
2,650
22,922
2,911,532
Mosseri Marlio Charles
10% Owner
Feb 07 '25
Buy
5.00
240,000
1,200,000
2,884,121
BENTSUR RON
Chairman & CEO
Dec 24 '24
Buy
4.65
4,500
20,925
3,270,924
Mosseri Marlio Charles
10% Owner
Dec 13 '24
Buy
4.70
17,000
79,900
2,612,000
Poradosu Enrique
Chief Science & Business Off
Nov 19 '24
Buy
4.99
2,000
9,980
1,506,319
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):